These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 14973643)

  • 1. Use of infliximab, an anti-tumor necrosis alpha antibody, for inflammatory dermatoses.
    Drosou A; Kirsner RS; Welsh E; Sullivan TP; Kerdel FA
    J Cutan Med Surg; 2003; 7(5):382-6. PubMed ID: 14973643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infliximab in dermatological treatment: beyond psoriasis.
    Rigopoulos D; Korfitis C; Gregoriou S; Katsambas AD
    Expert Opin Biol Ther; 2008 Jan; 8(1):123-33. PubMed ID: 18081542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of the use of infliximab to manage cutaneous dermatoses.
    Gupta AK; Skinner AR
    J Cutan Med Surg; 2004; 8(2):77-89. PubMed ID: 15685387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions.
    Oh CJ; Das KM; Gottlieb AB
    J Am Acad Dermatol; 2000 May; 42(5 Pt 1):829-30. PubMed ID: 10775863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pityriasis rubra pilaris: failure of combination treatment with acitretin and infliximab.
    Lu R; George SJ; Hsu S
    Dermatol Online J; 2006 May; 12(4):18. PubMed ID: 17083873
    [No Abstract]   [Full Text] [Related]  

  • 6. Targeting tumor necrosis factor alpha. New drugs used to modulate inflammatory diseases.
    LaDuca JR; Gaspari AA
    Dermatol Clin; 2001 Oct; 19(4):617-35. PubMed ID: 11705350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab for hidradenitis suppurativa.
    Sullivan TP; Welsh E; Kerdel FA; Burdick AE; Kirsner RS
    Br J Dermatol; 2003 Nov; 149(5):1046-9. PubMed ID: 14632813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progressive cutaneous sarcoidosis responding to anti-tumor necrosis factor-alpha therapy.
    Mallbris L; Ljungberg A; Hedblad MA; Larsson P; Ståhle-Bäckdahl M
    J Am Acad Dermatol; 2003 Feb; 48(2):290-3. PubMed ID: 12582407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of infliximab in pityriasis rubra pilaris is associated with pro-inflammatory cytokine inhibition.
    Adnot-Desanlis L; Antonicelli F; Tabary T; Bernard P; Reguiaï Z
    Dermatology; 2013; 226(1):41-6. PubMed ID: 23548788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab: a promising new treatment option for ulcerated necrobiosis lipoidica.
    Kolde G; Muche JM; Schulze P; Fischer P; Lichey J
    Dermatology; 2003; 206(2):180-1. PubMed ID: 12592093
    [No Abstract]   [Full Text] [Related]  

  • 11. [Treatment of severe refractory psoriasis with infliximab].
    Mahiques Santos L; Martínez-Menchón T; Sánchez Carazo JL; Oliver Martínez V; Soriano Navarro CJ; Fortea Baixauli JM
    Med Clin (Barc); 2004 Nov; 123(17):657-8. PubMed ID: 15563800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab.
    Schopf RE; Aust H; Knop J
    J Am Acad Dermatol; 2002 Jun; 46(6):886-91. PubMed ID: 12063486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab for the treatment of psoriasis.
    Kleyn CE; Griffiths CE
    Expert Opin Biol Ther; 2006 Aug; 6(8):797-805. PubMed ID: 16856801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TNF-α antagonists beyond approved indications: stories of success and prospects for the future.
    Karampetsou MP; Liossis SN; Sfikakis PP
    QJM; 2010 Dec; 103(12):917-28. PubMed ID: 20802008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre.
    Antoniou C; Stefanaki I; Stratigos A; Moustou E; Vergou T; Stavropoulos P; Avgerinou G; Rigopoulos D; Katsambas AD
    Br J Dermatol; 2010 May; 162(5):1117-23. PubMed ID: 19906069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-alpha, in the treatment of Crohn's disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy? The Infliximab User Group.
    Mortimore M; Gibson PR; Selby WS; Radford-Smith GL; Florin TH;
    Intern Med J; 2001 Apr; 31(3):146-50. PubMed ID: 11478343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab in psoriasis and psoriatic arthritis.
    Papoutsaki M; Osório F; Morais P; Torres T; Magina S; Chimenti S; Costanzo A
    BioDrugs; 2013 Jan; 27 Suppl 1():13-23. PubMed ID: 23990278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcending conventional therapies: the role of biologic and other novel therapies.
    Sandborn WJ
    Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S9-16. PubMed ID: 11380043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of treatment with chimeric monoclonal antibody (Infliximab) to tumor necrosis factor-alpha for Crohn's disease in Japan: evaluation by rapid turnover proteins, and radiologic and endoscopic findings.
    Asakura H; Yao T; Matsui T; Koganei K; Fukushima T; Takazoe M; Hobara R; Nakano H; Okamura S; Matsueda K; Kashida H; Makiyama K; Hiwatashi N; Kashiwagi K; Hibi T
    J Gastroenterol Hepatol; 2001 Jul; 16(7):763-9. PubMed ID: 11446884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effectiveness of tumor necrosis factor alpha antibody (infliximab) in treating recalcitrant psoriasis: a report of 2 cases.
    O'Quinn RP; Miller JL
    Arch Dermatol; 2002 May; 138(5):644-8. PubMed ID: 12020227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.